Cargando…

Anti-TNF-Alpha Therapy and Systemic Vasculitis

TNF-α is a pleiotropic cytokine, which plays a major role in the pathogenesis of numerous autoimmune and/or inflammatory systemic diseases. Systemic vasculitis constitutes a group of rare diseases, characterized by inflammation of the arterial or venous vessel wall, causing stenosis and thrombosis....

Descripción completa

Detalles Bibliográficos
Autores principales: Jarrot, Pierre-André, Kaplanski, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955590/
https://www.ncbi.nlm.nih.gov/pubmed/24719524
http://dx.doi.org/10.1155/2014/493593
_version_ 1782307592668708864
author Jarrot, Pierre-André
Kaplanski, Gilles
author_facet Jarrot, Pierre-André
Kaplanski, Gilles
author_sort Jarrot, Pierre-André
collection PubMed
description TNF-α is a pleiotropic cytokine, which plays a major role in the pathogenesis of numerous autoimmune and/or inflammatory systemic diseases. Systemic vasculitis constitutes a group of rare diseases, characterized by inflammation of the arterial or venous vessel wall, causing stenosis and thrombosis. Treatment of the different type of vasculitis mainly relies on steroids and immunosuppressive drugs. In case of refractory or relapsing diseases, however, a second line of treatment may be required. Anti-TNF-α drugs have been used in this setting during the last 15 years with inconsistent results. We reviewed herein the use of anti-TNF-α therapy in different kind of vasculitis and concluded that, except for Behcet's disease, this therapeutic option has not demonstrated significant improvement in the treatment of vasculitis.
format Online
Article
Text
id pubmed-3955590
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-39555902014-04-09 Anti-TNF-Alpha Therapy and Systemic Vasculitis Jarrot, Pierre-André Kaplanski, Gilles Mediators Inflamm Review Article TNF-α is a pleiotropic cytokine, which plays a major role in the pathogenesis of numerous autoimmune and/or inflammatory systemic diseases. Systemic vasculitis constitutes a group of rare diseases, characterized by inflammation of the arterial or venous vessel wall, causing stenosis and thrombosis. Treatment of the different type of vasculitis mainly relies on steroids and immunosuppressive drugs. In case of refractory or relapsing diseases, however, a second line of treatment may be required. Anti-TNF-α drugs have been used in this setting during the last 15 years with inconsistent results. We reviewed herein the use of anti-TNF-α therapy in different kind of vasculitis and concluded that, except for Behcet's disease, this therapeutic option has not demonstrated significant improvement in the treatment of vasculitis. Hindawi Publishing Corporation 2014 2014-02-27 /pmc/articles/PMC3955590/ /pubmed/24719524 http://dx.doi.org/10.1155/2014/493593 Text en Copyright © 2014 P.-A. Jarrot and G. Kaplanski. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Jarrot, Pierre-André
Kaplanski, Gilles
Anti-TNF-Alpha Therapy and Systemic Vasculitis
title Anti-TNF-Alpha Therapy and Systemic Vasculitis
title_full Anti-TNF-Alpha Therapy and Systemic Vasculitis
title_fullStr Anti-TNF-Alpha Therapy and Systemic Vasculitis
title_full_unstemmed Anti-TNF-Alpha Therapy and Systemic Vasculitis
title_short Anti-TNF-Alpha Therapy and Systemic Vasculitis
title_sort anti-tnf-alpha therapy and systemic vasculitis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955590/
https://www.ncbi.nlm.nih.gov/pubmed/24719524
http://dx.doi.org/10.1155/2014/493593
work_keys_str_mv AT jarrotpierreandre antitnfalphatherapyandsystemicvasculitis
AT kaplanskigilles antitnfalphatherapyandsystemicvasculitis